Patent 5665704 Issued on September 9, 1997. Estimated Expiration Date: May 25, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
Human receptor selective atrial natriuretic factor variants containing various substitutions, especially G16R, show equal potency and binding affinity for the human A-receptor but have decreased affinity for the human clearance or C-receptor. These ANF variants have natriuretic, diuretic and vasorelaxant activity but have increased metabolic stability, making them suitable for treating congestive heart failure, acute kidney failure and renal hypertension.
Rudinger, J. (1976). Peptide Hormones. (ed. J.A. Parsons). University Park Press. Baltimore. pp. 1-7 Jun. 1976
Bush et al., "Vasorelaxant Potencies and Receptor Binding Affinities of Atrial Natriuretic Hormone (ANH) Analogues" Fed. Proc. (Abstract Only) 45:657,2919 (1986)
Cunningham et al., "Production of an Atrial Natriuretic Peptide Variant that is Specific for Type A Receptor" EMBO Journal 13(11):2508-2515 (1994)
Dayhoff et al., "A Model of Evolutionary Change in Proteins" Atlas of Protein Sequence & Structure 5:89-99 (1972)
Kanagawa et al., "Purification and Complete Amino Acid Sequence of -Human Atrial Natriuretic Polypeptide (-hANP)" Biochem Biophys Res. Comm. 118(1):131-139 (1984)
Nutt et al., "Chemical Synthesis and Structure-Activity Relations for ANF Analogues" Endocrinology and Metabolism Clinics of North America 16(1):19-41 (1987)
Olins et al., "A Linear Analog of Atrial Natriuretic Peptide (ANP) Discriminates Guanylate Cyclase-coupled ANPn Receptors from Non-coupled Receptors" The Journal of Biological Chemistry 263(22):10989-10993 (1988